These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34256819)

  • 21. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
    Blair HA
    Drugs; 2018 Dec; 78(18):1903-1910. PubMed ID: 30511323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
    Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
    Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
    Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
    J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
    Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
    Chen EC; Fathi AT; Brunner AM
    Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
    Lee D; Jain AG; Deutsch Y; Eatrides J; Chan O; Padron E; Kuykendall A; Komrokji R; Lancet J; Sallman D; Talati C; Sweet K
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):774-779. PubMed ID: 35760672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
    Cortes J; Pérez-García J; Whiting S; Wan Y; Solem C; Tai MH; Margunato-Debay S; Ko A; Fandi A; Botteman M
    Clin Breast Cancer; 2018 Oct; 18(5):e919-e926. PubMed ID: 29703690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
    Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
    Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
    Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.
    Bertoli S; Tavitian S; Bories P; Luquet I; Delabesse E; Comont T; Sarry A; Huguet F; Bérard E; Récher C
    Cancer Med; 2019 Jul; 8(8):3846-3854. PubMed ID: 31173485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
    Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
    Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alotaibi S; Niederwieser D; Ahmed SO; Sanz J; Mohty M; Aljurf M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):575-580. PubMed ID: 35418351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
    McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
    Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
    Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
    J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.